Alpha Thalassemia clinical trials at UCSF

3 in progress, 1 open to eligible people

Alpha thalassemia is a medical condition affecting the body's ability to produce hemoglobin. UCSF is gathering information worldwide from individuals with this condition. The goal is to document experiences and outcomes from fetal development onward.

Showing trials for

  • International Registry of Patients With Alpha Thalassemia

    open to all eligible people

    This is an international prospective registry of patients with Alpha thalassemia to understand the natural history of the disease and the outcomes of fetal therapies, with the overall goal of improving the prenatal management of patients with Alpha thalassemia.

    San Francisco 5391959, California 5332921

  • Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)

    Sorry, in progress, not accepting new patients

    The primary objective of this study was to compare the effect of mitapivat versus placebo on transfusion burden in participants with α- or β-transfusion-dependent thalassemia.

    Oakland 5378538, California 5332921 and other locations

  • Etavopivat in Patients With Thalassemia or Sickle Cell Disease

    Sorry, in progress, not accepting new patients

    This clinical trial is a Phase 2 study that will evaluate the safety and clinical activity of etavopivat in patients with thalassemia or sickle cell disease and test how well etavopivat works to lower the number of red blood cell transfusions required and increase hemoglobin.

    Oakland 5378538, California 5332921 and other locations

Our lead scientists for Alpha Thalassemia research studies include .

Last updated: